Fierce Healthcare July 11, 2019
Startup Medicare Advantage (MA) insurer Clover Health has launched a new drug development subsidiary called Clover Therapeutics.
The new arm launched alongside its first partnership, a research collaboration with Roche subsidiary Genentech that will focus on the genetic factors that can put people at risk for developing ocular diseases, Clover announced.
“Clover Therapeutics was created to address the significant unmet needs in chronic progressive diseases in the Medicare population,” Cheng Zhang, head of the subsidiary, said.
“By partnering with our members to study the clinical and genetic drivers of ocular diseases, combined with Genentech’s pioneering history of drug discovery and development in this area, we to improve the quality of life for seniors living with these conditions,”...
Today's Sponsors
Today's Sponsor